Vol. 2 No. 12 (2022)
Reimbursement Reviews

Selpercatinib (Retevmo)

Published December 22, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses selpercatinib (Retevmo), 40 mg and 80 mg capsules, oral.
  • Indication: For the treatment of RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.